CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Outcome of Aflibercept-Bevacizumab Alternate Dosing in Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept
Daeun Shin, Jae Hui Kim
J Korean Ophthalmol Soc. 2022;63(6):526-534.   Published online June 15, 2022
DOI: https://doi.org/10.3341/jkos.2022.63.6.526

Excel Download

Outcome of Aflibercept-Bevacizumab Alternate Dosing in Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept
Journal of the Korean Ophthalmological Society. 2022;63(6):526-534   Crossref logo
Link1 Link2 Link3

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
Clinical Ophthalmology. 2015;1315   Crossref logo
Link1

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
Clinical Ophthalmology. 2014;2129   Crossref logo
Link1

Short-term Efficacy of Brolucizumab Injection for Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept
Journal of Retina. 2021;6(2):145-149   Crossref logo
Link1 Link2

<p>Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration</p>
Clinical Ophthalmology. 2019;Volume 13:1289-1295   Crossref logo
Link1 Link2

Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’
Eye. 2017;32(2):477-479   Crossref logo
Link1 Link2 Link3 Link4

Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration
Value in Health. 2014;17(3):A287   Crossref logo
Link1 Link2

Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab
Taiwan Journal of Ophthalmology. 2014;4(1):40-44   Crossref logo
Link1 Link2

Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration
Acta Ophthalmologica. 2015;93:n/a-n/a   Crossref logo
Link1 Link2

Reply to: ‘Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’
Eye. 2017;32(2):479-481   Crossref logo
Link1 Link2 Link3 Link4